BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin ...

Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, July 02, 2025 (GLOBE NEWSWIRE) -- The Global Research Collaboration is a research and exclusive license option agreement with Shionogi to ...

Storied Japanese pharma Shionogi is upping its arsenal in the fight against antibiotic resistance. | Storied Japanese pharma ...

BioVersys & Shionogi ink global research collaboration for broad-spectrum NTM clinical candidate: Basel, Switzerland Thursday, July 3, 2025, 10:00 Hrs [IST] BioVersys AG, a multi- ...

Swiss biopharma company BioVersys (today announced a research and exclusive license option agreement with the Japanese ...

Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...

Shionogi will pay BioVersys $6.3 million for developing BV500, BioVersys's drug candidate for non-tuberculous mycobacteria.

A digital therapeutic (DTx) for attention deficit hyperactivity disorder (ADHD) developed by Akili has been approved in Japan, where it will be sold by licensee Shionogi. The DTx – known as ...

Review Shionogi & Co Ltd ADR (SGIOY:PINX) stock and the current sustainability and ESG risk rating to help with your investing decisions.

Review which funds and institutions currently hold Shionogi & Co Ltd ADR (SGIOY:PINX) stock for ownership information.

More than 65 new companies debut on the FleetOwner 500: Private, which ranks the biggest American transportation organizations for non-trucking companies.